Close Menu

NIPT

By early 2020, the UK company plans to develop a version of its Iona test that uses Illumina's sequencing technology.

A randomized clinical trial from France revealed similar miscarriage rates in women who had cell-free DNA screening for trisomy 21 prior to invasive testing.

The firm recognized $63.1 million in revenues and processed 162,807 tests in the second quarter 2018.

The partners will test PerkinElmer's Vanadis NIPT platform on samples from 2,650 women to determine detection and false positive rates.

The report states that using NIPD for trisomy 21 in high-risk women could "probably reduce" the total number of invasive tests though the data is incomplete.

Under the agreement, the companies plan to develop a customized solution that can be widely deployed for DNA sequencing.

Cooper took a $24.4 million impairment charge in the second quarter on the intangible assets it acquired in 2016 from carrier screening firm Recombine.

The UK-based noninvasive prenatal testing firm also said that it has raised £2.5 million in funding through a share subscription.

The firm said it would likely do a joint submission of its ctDNA assay to the FDA and CMS for approval and a national coverage determination.

The molecular diagnostics firm recognized $62.3 million in first quarter 2018 revenues, and it processed more than 164,000 tests.

Pages